imo, at current levels, ARIA still offers the most upside (on a risk-adjusted basis). fwiw, back of the envelope - here are the targets I've had for over a year:
$6 to $8 pre-Rida filing $8 to $10 post-filing $12 upon rida approval. add $3 for ponatinib at NDA and $8 at approval.
2011 target is right around $12. 2012 target is $18 to $20 with the ALK inhibitor the wildcard.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.